FDG-PET status following chemoradiotherapy provides high management impact and powerful prognostic stratification in oesophageal cancer
- PMID: 16550384
- DOI: 10.1007/s00259-005-0040-z
FDG-PET status following chemoradiotherapy provides high management impact and powerful prognostic stratification in oesophageal cancer
Abstract
Purpose: The purpose of this study was to evaluate the impact of FDG-PET following chemoradiotherapy (CRT) on treatment planning and survival in patients with oesophageal cancer (OC).
Methods: Fifty-three consecutive OC patients had a post-treatment PET scan to evaluate tumour response to CRT prior to possible surgery. Baseline pre-CRT PET was performed in 33 patients. Prospectively recorded post-CRT management plans were compared with post-PET treatment. High impact was defined as a change in treatment intent or modality. Survival was analysed using the Kaplan-Meier product limit method and Cox proportional hazards regression model.
Results: After completion of CRT, 23/53 patients (43%) achieved complete metabolic response (CMR), as compared with only four (8%) with complete response on computed tomography. High PET impact was observed in 19 patients (36%). CMR was strongly predictive of survival (p<0.008) on multivariate analysis. CMR patients in whom resection was not performed had comparable survival to those (CMR and non-CMR) who underwent resection.
Conclusion: The use of post-treatment FDG-PET for assessment of tumour response after CRT changed the clinical management of more than one-third of OC patients. CMR status as assessed by PET powerfully stratified prognosis. Even in the absence of a baseline study, normalisation of uptake at all sites of known tumoral involvement carries a good medium-term prognosis.
Similar articles
-
The added value of metabolic imaging with FDG-PET in oesophageal cancer: prognostic role and prediction of response to treatment.Eur J Nucl Med Mol Imaging. 2006 Jul;33(7):753-8. doi: 10.1007/s00259-006-0147-x. Eur J Nucl Med Mol Imaging. 2006. PMID: 16733687 Review. No abstract available.
-
Significant clinical impact and prognostic stratification provided by FDG-PET in the staging of oesophageal cancer.Eur J Nucl Med Mol Imaging. 2006 Jul;33(7):759-69. doi: 10.1007/s00259-005-0028-8. Epub 2006 Feb 10. Eur J Nucl Med Mol Imaging. 2006. PMID: 16470369 Clinical Trial.
-
Value of complete metabolic response by (18)F-fluorodeoxyglucose-positron emission tomography in oesophageal cancer for prediction of pathologic response and survival after preoperative chemoradiotherapy.Eur J Cancer. 2007 Jun;43(9):1385-91. doi: 10.1016/j.ejca.2007.04.001. Epub 2007 May 23. Eur J Cancer. 2007. PMID: 17512192 Clinical Trial.
-
18F-FDG PET/CT has a high impact on patient management and provides powerful prognostic stratification in the primary staging of esophageal cancer: a prospective study with mature survival data.J Nucl Med. 2012 Jun;53(6):864-71. doi: 10.2967/jnumed.111.101568. Epub 2012 May 11. J Nucl Med. 2012. PMID: 22582047
-
Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer.Ann Thorac Surg. 2004 Oct;78(4):1152-60; discussion 1152-60. doi: 10.1016/j.athoracsur.2004.04.046. Ann Thorac Surg. 2004. PMID: 15464463 Review.
Cited by
-
Positron Emission Tomography's Utility in Esophageal Cancer Management.J Thorac Dis. 2009 Dec;1(1):29-33. J Thorac Dis. 2009. PMID: 22262999 Free PMC article.
-
The added value of metabolic imaging with FDG-PET in oesophageal cancer: prognostic role and prediction of response to treatment.Eur J Nucl Med Mol Imaging. 2006 Jul;33(7):753-8. doi: 10.1007/s00259-006-0147-x. Eur J Nucl Med Mol Imaging. 2006. PMID: 16733687 Review. No abstract available.
-
[Esophageal squamous cell carcinoma: pre-operative combined radiochemotherapy from a surgical oncological viewpoint].Chirurg. 2009 Nov;80(11):1011-8. doi: 10.1007/s00104-009-1733-9. Chirurg. 2009. PMID: 19812907 Review. German.
-
Should FDG-PET imaging be considered on a routine basis in clinical trials for carcinoma of esophagus to assure uniformity of protocols among sites?Eur J Nucl Med Mol Imaging. 2007 Apr;34(4):604-5. doi: 10.1007/s00259-006-0315-z. Eur J Nucl Med Mol Imaging. 2007. PMID: 17206414 No abstract available.
-
Oesophageal cancer: assessment of response and follow up.Cancer Imaging. 2007 Oct 1;7 Spec No A(Special issue A):S67-9. doi: 10.1102/1470-7330.2007.9019. Cancer Imaging. 2007. PMID: 17921096 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials